sever
acut
respiratori
syndrom
sar
newli
emerg
infecti
diseas
human
centuri
appear
guangdong
provinc
southern
china
novemb
spread
countri
five
contin
along
intern
air
travel
rout
caus
larg
scale
outbreak
hong
kong
singapor
toronto
earli
world
health
organis
issu
global
alert
sar
march
support
author
affect
region
implement
epidemiolog
surveil
adher
infectioncontrol
procedur
includ
patient
isol
quarantin
contact
help
contain
sar
outbreak
midjuli
howev
total
sar
case
associ
death
aetiolog
agent
sar
identifi
coronaviru
cov
genom
sequenc
establish
novel
member
famili
novel
cov
satisfi
koch
postul
causat
consist
isol
sar
patient
viral
isol
reproduct
diseas
nonhuman
primat
inocul
presenc
specif
antibodi
respons
viru
patient
experiment
infect
primat
remark
find
accomplish
within
month
issu
global
alert
sar
testifi
rapid
respons
collabor
intern
research
effort
deal
emerg
pandem
origin
sar
remain
uncertain
despit
close
relat
cov
recov
civet
cat
anim
guangdong
provinc
suggest
sarscov
could
origin
anim
implic
sar
zoonot
diseas
member
cov
famili
caus
fatal
diseas
poultri
laboratori
rodent
two
previous
known
human
cov
caus
mild
upper
respiratori
infect
despit
sar
epidem
eventu
control
case
isol
still
neither
effect
treatment
sar
efficaci
vaccin
prevent
infect
high
morbid
mortal
sar
well
potenti
reemerg
make
paramount
focu
futur
research
develop
effect
mean
treat
prevent
diseas
reappear
inde
sporad
reemerg
case
report
guangdong
provinc
well
research
laboratori
summari
sever
acut
respiratori
syndrom
sar
new
infecti
diseas
centuri
pandem
potenti
novel
coronaviru
cov
identifi
aetiolog
agent
genom
sequenc
within
month
world
health
organis
issu
global
threat
sar
high
morbid
mortal
potenti
pandem
infect
demand
rapid
research
respons
develop
effect
antivir
treatment
vaccin
depend
understand
pathogenesi
immun
respons
sar
cov
understand
ecolog
sar
cov
human
anim
help
prevent
futur
cross
speci
transmiss
likewis
superspread
event
clarif
underli
reason
import
prevent
larg
scale
outbreak
sar
lastli
utmost
import
intern
research
collabor
strengthen
deal
sar
emerg
infecti
diseas
serious
threaten
futur
elsevi
ltd
right
reserv
singapor
taiwan
beij
sinc
conclus
sar
epidem
may
nation
institut
allergi
infecti
diseas
niaid
conven
colloquium
entitl
sar
develop
research
respons
nation
institut
health
campu
particip
includ
physician
scientist
policymak
unit
state
china
canada
europ
elsewher
coordin
robust
research
respons
sar
threat
follow
five
area
clinic
research
epidemiolog
diagnost
therapeut
vaccin
one
year
gone
sinc
colloquium
intens
research
activ
conduct
mani
laboratori
worldwid
address
issu
rais
despit
publish
paper
pubm
variou
aspect
sar
mani
question
still
await
answer
review
attempt
highlight
import
issu
partial
address
point
area
clinic
interest
rather
cover
aspect
comprehens
care
descript
clinic
manifest
sar
correl
virolog
immunolog
paramet
suggest
initi
viral
replic
phase
day
possibl
follow
immunopatholog
phase
hypothesis
immunopatholog
respons
trigger
viral
antigen
henc
strateg
treatment
stop
viral
replic
initi
phase
diseas
peak
viral
load
subsequ
damag
minimis
therefor
effect
antivir
treatment
window
opportun
sever
day
diseas
onset
modifi
peak
viral
load
therebi
theori
decreas
morbid
mortal
present
treatment
larg
empir
therefor
controversi
rang
support
therapi
without
intervent
combin
antivir
steroid
recent
report
open
trial
combin
proteas
inhibitor
nucleosid
analogu
histor
control
suggest
favour
clinic
respons
use
lopinavirritonavir
ribavirin
howev
controversi
remain
control
studi
undertaken
need
set
intern
clinic
trial
network
develop
perform
clinic
protocol
sar
reappear
futur
research
prioriti
sar
therapeut
focu
antivir
drug
screen
clinic
proven
candid
exist
highthroughput
screen
assay
develop
appli
exist
drug
candid
librari
vitro
activ
sar
cov
observ
certain
prepar
interferona
well
glycyrrhizin
vivo
activ
also
demonstr
interferona
nonhuman
primat
model
studi
human
molecular
studi
sar
cov
coronavirus
suggest
sever
potenti
molecular
target
antivir
drug
includ
viral
bind
fusion
activ
mediat
glycoprotein
spike
cov
surfac
well
rnadepend
rna
polymeras
cystein
proteas
identif
angiotensinconvert
enzym
function
receptor
sar
cov
open
possibl
treatment
strategi
interfer
bind
fusion
sar
cov
target
cell
sar
cov
surfac
spike
protein
contain
domain
metallopeptidas
bind
domain
sar
cov
protein
effici
shown
block
sar
cov
replic
vitro
use
vero
cell
experiment
model
number
antibodi
peptid
small
compound
bind
possibl
use
treatment
sar
either
block
sproteinbind
site
induc
conform
favour
bind
fusion
solubl
form
may
slow
viral
replic
infect
individu
recent
human
monoclon
antibodi
domain
sar
cov
develop
potent
neutralis
sar
cov
infect
effici
inhibit
syncytia
format
block
receptor
bind
monoclon
antibodi
use
immedi
treatment
strategi
emerg
prophylaxi
treatment
sar
timeconsum
develop
vaccin
new
drug
underway
winter
spring
month
diagnost
challeng
differenti
sar
respiratori
infect
great
make
rapid
simpl
accur
diagnost
assay
sar
cov
imper
public
health
tool
control
futur
sar
outbreak
well
initi
treatment
protocol
first
gener
pcr
assay
sar
cov
far
satisfactori
realtim
pcr
coupl
improv
rna
extract
method
allow
detect
viral
rna
nasopharyng
aspir
specif
know
bodi
viru
found
differ
stage
diseas
might
lead
new
diagnost
strategi
exampl
report
sar
cov
replic
peripher
blood
cell
sar
patient
shortli
onset
indic
blood
could
use
appropri
clinic
specimen
diagnosi
nevertheless
avail
highli
sensit
specif
direct
detect
method
sar
cov
readili
obtain
clinic
specimen
nasopharyng
secret
ideal
obviat
need
labori
step
rna
extract
serolog
assay
use
earli
diagnosi
igg
antibodi
appear
day
onset
symptom
state
igm
antibodi
typic
appear
earlier
detect
igm
antibodi
appear
permit
earlier
diagnosi
sinc
sar
patient
late
seroconvers
best
test
convalesc
serum
collect
least
day
prefer
day
onset
symptom
rule
sar
present
wide
use
method
detect
antibodi
sar
cov
indirect
immunofluoresc
assay
elisa
cellcultur
extract
difficult
standardis
therefor
recombinantantigenbas
elisa
assay
develop
use
highli
immunogen
nucleocapsid
protein
sar
cov
use
larg
scale
epidemiolog
studi
seropreval
characteris
immun
respons
sar
cov
includ
impact
sar
immun
function
immunopatholog
respons
viru
may
trigger
crucial
help
develop
new
therapeut
strategi
vaccin
rapid
generalis
lymphopaenia
patient
sar
acut
phase
infect
distinct
contrast
prolif
respons
seen
hiv
cmvor
ebvinfect
patient
patient
recov
sar
equal
rapid
dramat
restor
cell
b
cell
nk
cell
count
seen
peripher
blood
mechan
sar
cov
precipit
lymphopaenia
rapidli
unclear
could
relat
immunolog
trigger
apoptosi
uninfect
lymphocyt
elucid
underli
mechan
may
help
design
treatment
strategi
initi
increas
viral
load
first
day
diseas
also
suggest
role
innat
immun
firstlin
defenc
import
may
influenc
subsequ
diseas
progress
import
identifi
host
innat
immun
respons
genet
predictor
diseas
suscept
progress
would
help
improv
prognost
capabl
allow
identif
patient
like
benefit
aggress
intervent
inform
also
valu
develop
entri
criteria
intervent
studi
sinc
immun
respons
might
play
role
sar
pathogenesi
one
must
cautiou
possibl
enhanc
diseas
immunis
subject
inde
occur
experiment
vaccin
direct
felin
infecti
periton
viru
also
coronaviru
therefor
caution
urg
develop
sar
vaccin
howev
given
urgent
need
safe
effect
sar
vaccin
multipl
strategi
vaccin
develop
pursu
simultan
least
candid
sar
vaccin
differ
phase
develop
includ
develop
liveattenu
inactiv
viru
vaccin
addit
strategi
elicit
strong
cell
respons
dnabas
vaccin
engin
adenoviru
vector
well
elicit
product
neutralis
antibodi
subunit
vaccin
base
protein
fragment
peptid
also
develop
sar
cov
protein
express
attenu
vaccinia
viru
shown
immunis
mice
protect
similarli
dna
vaccin
encod
sar
cov
protein
induc
cell
neutralis
antibodi
respons
well
protect
immun
mous
model
viral
replic
reduc
six
order
magnitud
lung
mice
vaccin
plasmid
dna
express
vector
protect
mediat
humor
tcelldepend
immun
mechan
experiment
test
candid
sar
vaccin
would
requir
anim
model
reproduc
sar
symptom
patholog
human
howev
anim
model
describ
date
reliabl
mimic
respiratori
symptom
seen
human
sar
even
macaqu
model
use
initi
fulfil
last
koch
postul
confirm
sar
cov
etiolog
agent
alway
reproduc
sarslik
symptom
infect
sar
cov
could
due
macaqu
inbr
like
mice
find
consist
sar
anim
model
use
test
potenti
drug
vaccin
certainli
top
research
prioriti
monkey
mous
ferret
use
anim
model
answer
differ
research
question
origin
sar
cov
ecolog
relationship
anim
cov
certainli
import
topic
research
anim
reservoir
cov
constant
potenti
sourc
anoth
sar
outbreak
understand
ecolog
help
implement
measur
minimis
transmiss
across
speci
take
place
nevertheless
recent
sporad
reemerg
sar
due
laps
secur
research
laboratori
handl
sar
cov
testifi
urgent
need
maintain
monitor
laboratori
safeti
research
institut
deal
pathogen
anoth
mysteri
sar
epidemiolog
socal
superspread
event
commun
outbreak
amoy
garden
hous
complex
hong
kong
affect
resid
privat
hous
estat
tent
evid
airborn
transmiss
sar
cov
suggest
epidemiolog
analysi
outbreak
coupl
airflow
simul
experiment
studi
better
understand
superspread
event
crucial
prevent
similar
event
happen
sporad
case
sar
may
continu
appear
vigor
public
health
measur
maintain
anoth
major
outbreak
unlik
make
imposs
perform
control
clinic
studi
either
candid
antivir
vaccin
sar
cov
nevertheless
global
commun
need
prepar
emerg
reemerg
infecti
diseas
human
race
futur
understand
pathogenesi
immun
respons
sar
cov
develop
effect
antivir
therapeut
efficaci
vaccin
develop
rapid
accur
diagnost
test
earli
diagnosi
sar
cov
infect
clarifi
ecolog
human
anim
sar
cov
prevent
cross
speci
transmiss
understand
reason
superspread
event
